Clinical trials: Acute Circulatory Failure
Heart Failure, ADHF
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease…
- Conditions
- Heart Failure, ADHF, Acute MI
- Trial name
- COMPASSION (NCT04905160)
- Testing
- COMPASSION Digital Biomarker
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Aventyn, Inc.
Heart Failure
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
The purpose of this study is to determine the minimum effective dose of Istaroxime, in patients requiring hospitalization for deterioration of chronic heart failure and left ventricular systolic dysfunction.
- Trial name
- HORIZON-HF (NCT00616161)
- Testing
- Istaroxime
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Heart Failure, Acute Coronary Syndromes
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）
The aim of the study is to evaluate diagnostic performance of N-terminal Brain natriuretic Peptide (NT-proBNP) in acute heart failure among Chinese population.
- Trial name
- NT-proBNP，HF (NCT06691477)
- Testing
- No Interventions
- Where
- 4 sites in China
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Acute Decompensated Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
The purpose of this observational study is to collect and characterize multiple physiologic data from a broad subset of subjects with acute heart failure (HF) Changes in physiologic data are expected to correlate with 30-day…
- Trial name
- READMIT-HF (NCT01574144)
- Testing
- AVIVO™ PiiX Patch Monitor System
- Where
- 8 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
Acute Lung Injury, Systemic Inflammatory Response Syndrome
Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
The purpose of this study is to confirm the efficacy and safety of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome.
- Trial name
- NCT00219375
- Testing
- Sivelestat sodium hydrate
- Where
- 9 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acute Heart Failure
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
- Trial name
- NCT01543854
- Testing
- RLX030
- Where
- 20 sites in Argentina, Germany and 4 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Stent Thrombosis, Ischemic Stroke
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
The goal of this study is to predict and prevent adverse drug events by investigating the impact of genetic variants, demographics, and environmental factors in subjects status post myocardial infarction and percutaneous coronary…
- Conditions
- Stent Thrombosis, Ischemic Stroke, Myocardial Infarction, Acute Coronary Syndrome
- Trial name
- CARES1 (NCT04580602)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Myocardial Infarction, Acute, Heart Failure, Left Sided
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction…
- Trial name
- HF-REVERT (NCT05350969)
- Testing
- CDR132L
- Where
- 49 sites in Czechia, Germany and 6 more
- Volunteers
- 294 people
- Sponsor
- Cardior Pharmaceuticals GmbH
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
- Trial name
- DILATE (NCT01172756)
- Testing
- Riociguat (BAY63-2521)
- Where
- 7 sites in Austria, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Bayer
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Acute Decompensated Heart Failure
Gas Exchange for Predicting Hospital Heart Failure Readmissions
To determine whether, and if so, which gas exchange parameters measured on the Shape-HF Cardiopulmonary Exercise Testing System predict 30 and 180 day re-hospitalization in subjects discharged from hospitalization for an episode…
- Trial name
- NCT01960218
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shape Medical Systems, Inc.
Heart Failure, Left Bundle Branch Block
High Septal Pacing for Cardiac Resynchronization Therapy
The purpose of this acute study is to perform a preliminary investigation of high septal right ventricular pacing in the vicinity of the His bundle region as an alternate or adjunctive means for cardiac resynchronization in…
- Conditions
- Heart Failure, Left Bundle Branch Block, Heart Disease
- Trial name
- HISTORY (NCT01325480)
- Testing
- Cardiac Pacing
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics